Why GLP-1 drugs cause hair loss (and how to stop it)

The short answer

Yes, hair loss shows up more often in people taking semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) than in people taking placebo. No, the drugs are not dissolving your hair follicles. The best-supported explanation: rapid, large weight loss puts physical stress on the body, and that stress pushes follicles into a shedding phase called telogen effluvium. It’s usually temporary and not universal. The evidence behind it is messier than most headlines suggest, and there’s no proven fix beyond addressing the trigger.

What the numbers actually say

A 2025 FAERS disproportionality analysis examined seven GLP-1 receptor agonists using FDA Adverse Event Reporting System data from 2016 to 2025. Only two drugs produced a statistically significant signal for alopecia: semaglutide (697 reports) and tirzepatide (620 reports). Exenatide had zero reports. Albiglutide, dulaglutide, liraglutide, and lixisenatide showed no significant signal at all.

The signal strengthened over time. Tirzepatide peaked in 2025 with 324 cases and a reporting odds ratio of 2.08 (95% CI 1.86-2.32). Semaglutide peaked in 2024 with 218 cases and a reporting odds ratio of 1.55 (95% CI 1.35-1.77). Women filed the overwhelming majority of reports: 91% of semaglutide cases and 92% of tirzepatide cases.

FAERS has a real limitation here. It’s a spontaneous-reporting system with no denominator, so researchers know how many reports came in but not how many total users never reported anything. The study’s authors say so directly: these ratios measure disproportionality, not proven causation.

Trial data adds weight to the signal. In the SURMOUNT-1 phase 3 trial of tirzepatide, alopecia appeared in 5.1% of all patients on the 5 mg dose, 4.9% on 10 mg, and 5.7% on 15 mg, versus 0.9% on placebo. Pooled SURMOUNT-1 and SURMOUNT-3 data showed alopecia in 5.4% of tirzepatide patients (119 of 2,183) versus 0.9% on placebo (22 of 2,221).

The FDA label for Zepbound breaks this down by sex instead of by dose, and the gap is stark: 7.1% of female patients reported hair loss versus 0.5% of male patients, against 1.3% of women and 0% of men on placebo. The label attributes this to weight reduction associated with treatment, not a direct drug effect. Why women are hit so much harder isn’t explained in this data, and no other source in this review clears it up either.

Why weight loss speed matters more than the drug itself

The strongest clue that this is about weight loss, not pharmacology, comes from dose and formulation comparisons.

One dataset cited in the systematic review on GLP-1 therapies and hair loss found alopecia in 6.9% of patients taking 50 mg/day oral semaglutide (23 of 334) versus 0.2% of patients taking 2.4 mg weekly subcutaneous semaglutide (1 of 407). That 2.4 mg weekly dose is Wegovy, and it’s the highest weekly dose approved for obesity, not a low dose. The 0.2% figure comes from a single dataset of 407 patients and is lower than what shows up elsewhere: large Wegovy product trials (N=2,116) found hair loss in about 3% of patients versus 1% on placebo, and that 3%-versus-1% split is the more representative figure for the injectable dose. Even taking the higher 3% figure, though, it’s still well below the 6.9% seen with the 50 mg oral dose. Same drug, notably different rates depending on formulation. Doses below 2 mg weekly were rarely linked to hair loss reports at all.

Among adolescents on Wegovy, hair loss was reported in about 4% versus 0% on placebo.

The pattern points one way: bigger, faster weight loss creates more physiologic strain, and that strain is what triggers shedding, not the GLP-1 mechanism itself. That fits what’s already known about telogen effluvium, which shows up after rapid weight loss, severe caloric restriction, surgery, illness, or major stress generally. If you’re cutting calories hard on one of these medications, read up on protecting muscle and protein intake during rapid weight loss. The same rapid-loss dynamics that stress hair follicles also strain muscle mass.

The evidence is not settled, and that matters

It would be easy to round this off to “GLP-1 drugs cause hair loss, case closed.” The data doesn’t support that level of certainty.

A 2026 systematic review pooling 2,905 patients across five studies found real inconsistency. Three of the five studies reported hair regrowth or improvement with tirzepatide. Only two reported hair loss as an adverse event. That’s not a unanimous literature. It’s a split one.

A retrospective cohort of 283 GLP-1 users, cited within that same systematic review, found the odds ratio for semaglutide pointed toward increased hair loss risk, while most findings for tirzepatide and telogen effluvium were not statistically significant, landing at a borderline p-value of .0537.

The same systematic review also cites a separate TriNetX cohort study of over 218,000 GLP-1 users that found tirzepatide carried a hazard ratio of 2.65 for telogen effluvium versus other weight-loss medications, and 1.61 versus bariatric surgery. That same analysis found no increased telogen effluvium risk at all for semaglutide or liraglutide. Different studies, same drugs, sometimes opposite conclusions.

A pooled estimate across studies put the alopecia incidence rate at 6.0 per 1,000 patient-years on GLP-1 drugs versus 0.8 per 1,000 patient-years on placebo, a roughly seven-fold difference in raw rates, though the pooled risk ratio reported by the study authors was more conservative at 3.40 (95% CI 1.18-9.81). That confidence interval is wide, and heterogeneity across studies was high (I²=67.77%). Something real is likely here. The size of the effect isn’t pinned down.

One more point worth stating plainly: there’s little evidence linking GLP-1 use to alopecia areata, the autoimmune form of patchy hair loss, or to scarring alopecia. What this research describes is almost entirely telogen effluvium and, less often, androgenetic (pattern) hair loss.

What telogen effluvium actually looks like

Telogen effluvium is diffuse shedding, not patchy bald spots. It typically starts 2-3 months after whatever triggered it, according to a review of telogen effluvium. That delay is why some people never connect the shedding to a dose increase or a big drop in weight months earlier.

The good news: it usually resolves on its own. About 95% of acute cases clear within 3-6 months once the trigger is addressed, though full cosmetic regrowth can take 12-18 months. Shedding that continues past 6 months counts as chronic and warrants a dermatology visit.

What actually helps

No FDA-approved treatment exists for telogen effluvium itself. Management means removing the trigger and correcting real deficiencies, not blanket supplementation.

Practical steps supported by the evidence:

• Slow the weight-loss pace. Risk tracks with how much and how fast you lose. If shedding starts, talk to your prescriber about a more gradual dose titration.
• Get enough protein. Rapid caloric restriction can cause transient nutritional deficiencies, including protein, that contribute to shedding. Don’t cut protein intake while losing weight fast.
• Check iron and zinc with bloodwork, not guesswork. Iron deficiency without anemia, marked by ferritin below 20 ng/mL, shows up in about 20% of telogen effluvium cases. Test before supplementing.
• Don’t expect biotin to fix it. Biotin and general multivitamins aren’t proven to help without a documented deficiency.
• Consider topical minoxidil for patterned hair loss specifically. It’s discussed in the literature as an option, but it doesn’t treat telogen effluvium itself.

None of this requires stopping your medication. If cost is part of the picture while you adjust dose or timeline, compare options like semaglutide cost per month or GLP-1 coupons and discounts before making changes based on price alone.

Frequently Asked Questions

Do Ozempic, Wegovy, Zepbound, or Mounjaro actually cause hair loss? There’s a real, measurable increase in reported hair loss with semaglutide and tirzepatide specifically. Not every GLP-1 drug shows this: exenatide, albiglutide, dulaglutide, liraglutide, and lixisenatide showed no significant signal in FAERS data. It’s also a minority effect, roughly 3-7% of users in trials versus about 1% on placebo, not something that happens to everyone.

Is it the drug, or the weight loss? The evidence leans toward weight loss and the physiologic stress that comes with it, not a direct toxic effect on follicles. The clearest clue: high-dose oral semaglutide (50 mg/day), linked to faster and larger weight loss, showed notably higher hair loss rates than the standard weekly injectable dose used in Wegovy, even though that injectable dose is the highest one approved for obesity, not a low one. Causality isn’t proven from observational data, though, and the exact mechanism is still unclear.

How long does it last, and does hair grow back? Telogen effluvium typically starts 2-3 months after the trigger and resolves within 3-6 months in about 95% of acute cases. Full regrowth can take 12-18 months. If shedding lasts longer than 6 months or looks patterned rather than diffuse, get it checked by a dermatologist.

What can I do to prevent or reduce it? Work with your prescriber on a slower dose titration, make sure you’re getting enough protein as you lose weight, and get bloodwork for iron and zinc instead of self-treating with supplements. Biotin has no proven benefit without a diagnosed deficiency. Topical minoxidil is an option for patterned hair loss, but nothing is FDA-approved specifically for telogen effluvium.

Should I stop my GLP-1 medication if I notice hair loss? That’s a conversation for your prescriber, not a decision to make alone. Some FAERS reports showed improvement after stopping the drug, but that data is observational and doesn’t prove the drug caused the shedding in the first place. Hair loss alone usually isn’t a reason to abandon an otherwise effective, medically supervised treatment. Weigh it against your results and talk to your doctor or a dermatologist, especially if the shedding is severe or doesn’t stop after 6-9 months.

This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.